VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Vandetanib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms VIP
- 06 Jun 2017 Primary endpoint (Overall survival duration) has not been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 29 Jan 2014 Accrual to date is 101% according to United Kingdom Clinical Research Network.